ExaGrid Reports Record Bookings and Revenue for Q2 2019
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup with data deduplication, today announced record bookings and revenue for the quarter’s end in June 2019. ExaGrid posted the best quarter in its history and is on path to post another record bookings and revenue year.
“This was our best bookings and revenue quarter in the history of the company,” said Bill Andrews, CEO and President of ExaGrid. “We had a record number of six-and-seven-figure new customer deals in the quarter, which is a trend that continues to build as we gain momentum in large organizations globally.”
In addition to record Q2 bookings and revenue, ExaGrid achieved the following:
- ExaGrid is expanding support in Chile, Switzerland, India, Indonesia and other countries. ExaGrid has sales staff all over the world including Argentina, Australia, Benelux, Brazil, Canada, Colombia, Czech Republic, Dubai, France, Germany, Hong Kong, Israel, Italy, Mexico, Nordics, Poland, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, United Kingdom, United States and many others.
- ExaGrid has built upon its strong strategic alliance partner relationships with Veeam Software, HYCU and Zerto. The expanded relationship with HYCU allows for further penetration into organizations deploying Nutanix with ESXi and AHV.
- Enhanced functionality allowing Commvault deduplication to remain turned on so that appliances behind can further deduplicate Commvault data by an additional 3X, which greatly reduces storage costs. ExaGrid is gaining momentum with Commvault customers.
- Voted Storage Magazine’s “Enterprise Backup Hardware Product of the Year” at its annual awards ceremony Storries XVI.
As the market matures, organizations realize the performance degradation that data deduplication can have on backup unless a solution is intentionally architected to prevent any such impact. All deduplication solutions reduce storage and WAN bandwidth to a degree, but only ExaGrid solves the three inherent compute problems to achieve faster backups, restores, and VM boots by leveraging its unique Landing Zone, Adaptive Deduplication, and scale-out architecture.
“First-generation deduplication solutions can be cost prohibitive for backup storage and are slow for backups, restores, and VM boots, which is why over 80% of ExaGrid’s newly-acquired customers are replacing Dell EMC Data Domain, HPE StoreOnce, and the Veritas NetBackup 5200/5300 series of appliances. We are replacing low cost primary storage disk behind Commvault, as ExaGrid is far less expensive than Cisco 3260, NTAP eSeries, HPE Nimble, Dell, etc. when customers require longer term retention,” Andrews said.
All backup storage vendors reduce storage and bandwidth to varying degrees, but most provide slow ingest rates due to deduplication being performed ‘inline.’ Additionally, other solutions only store deduplicated data, which causes restore speeds and VM boots to be very slow. ExaGrid’s ingest rate is 6X faster than its closest competitor. Unlike the first-generation vendors that only add capacity as data grows, ExaGrid appliances add compute with capacity, ensuring that the backup window remains fixed in length. Only ExaGrid uses a scale-out architecture with a unique loading zone, which holistically addresses all of the scalability and performance challenges of backup storage.
ExaGrid’s turnkey disk-based backup system combines enterprise storage with zone-level data deduplication, delivering a disk-based solution that is far more cost effective than low cost disk. Unlike first-generation inline/scale-up deduplication solutions that were either built into a backup application media server or into a dedicated storage appliance, ExaGrid delivers the backup industry’s only true landing zone and scale-out architecture with data deduplication. Utilizing ExaGrid’s landing zone with adaptive deduplication, typically halves the cost of the first-generation large brand solutions and is 3X the backup performance and 20X the restore/VM boot performance. By using a scale-out architecture, ExaGrid is the only solution that keeps the backup window fixed in length as data grows and eliminates both forklift upgrades and forced product obsolescence.
ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a
Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CET | Press release
Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin
Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CET | Press release
Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CET | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal
Traxens Presents Solutions for Port Industry at Smart Ports Barcelona13.11.2019 07:30:00 CET | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will present its smart asset tracking solutions at the Smart Ports Barcelona event, Smart Ports, Piers of the Future, November 19 to 21. Its tailored Industrial Internet of Things (IIoT) solutions are specifically designed to meet the needs of the port industry by providing near real-time insight into the end-to-end global supply chain. Traxens’ solution provides comprehensive, precise and timely data on cargo, through tracking logistic assets in transit anywhere in the world. Traxens’ patented breakthrough Internet of Things (IoT) technology brings improved efficiency and security, greater transparency and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain. With Traxens’ solutions, ports can improve their efficiency and the interoperability of the systems with a trusted third party. For example, the Cargo Commun
PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business13.11.2019 06:30:00 CET | Press release
PMC Group N.A., Inc. ("PMC") and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing conditions. The Business includes Lanxess’ global organotin catalyst, organotin specialties and intermediates product lines. The transaction includes a toll manufacturing agreement under which Lanxess will continue to manufacture certain products post-closing for PMC at its Bergkamen, Germany organometallics manufacturing facility. Mr. Debtosh Chakrabarti, President of PMC said, “This acquisition represents PMC’s continuing commitment to the organotin industry and is synergistic to our existing organometallics and catalyst businesses. We believe that the customer base of the Business as well as all of PMC’s customers will benefit significantly from combining the tec